Taken together, we identified CD137 as a novel positive immune checkpoint on human monocytes/macrophages, which can have therapeutic implications especially in view of an added therapeutic value when combining CD137 agonists with tumor-targeting mAbs. The gene discussed is TNFRSF9; the disease is neoplasm.